16 completed, 15 active not recruiting, 7 recruiting, 2 not yet recruiting. 43 Phase 3, 4 Phase 2.
Follow olaparib: new trials by email Literature Review of olaparib trials Research Report on olaparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 180 | 2026-09-01 | 2026-07-23 |
| Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib) - Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Not yet recruiting | The Netherlands Cancer Institute | 1000 | 2026-04-01 | 2026-03-20 |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin - Epithelial Ovarian Cancer, Ovarian Cancer | Phase 3 | Recruiting | Imunon | 500 | 2025-07-09 | 2026-10-30 |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Breast Neoplasms, Triple Negative Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 2400 | 2025-06-30 | 2026-10-13 |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 3 | Recruiting | NRG Oncology | 880 | 2025-03-12 | 2026-08-07 |
| Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer Olaparib (300 mg BID) - Endometrial Cancer, p53abn | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 554 | 2024-06-26 | 2026-01-20 |
| A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer Dato-DXd, Durvalumab, Pembrolizumab - Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1902 | 2023-11-14 | 2026-10-21 |
| Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2023-03-30 | 2026-10-01 |
| MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. Olaparib, Chemotherapy drug - Ovarian Cancer | Phase 3 | Recruiting | National Cancer Institute, Naples | 200 | 2022-01-21 | 2023-03-24 |
| Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected Alpelisib, Olaparib, Paclitaxel - Ovarian Cancer | Phase 3 | Terminated | Novartis Pharmaceuticals | 358 | 2021-07-22 | 2026-10-19 |
| Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) olaparib, abiraterone acetate - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Active not recruiting | AstraZeneca | 110 | 2021-06-24 | 2026-08-28 |
| D9319C00001- 1L OC Mono Global RCT Olaparib, Matching placebo - Ovarian Cancer | Phase 3 | Active not recruiting | AstraZeneca | 366 | 2021-05-31 | 2026-03-02 |
| Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline) - Small Cell Lung Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 672 | 2020-12-08 | 2026-09-24 |
| Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) Olaparib, 5-FU, Bevacizumab - Metastatic Colorectal Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 335 | 2020-08-19 | 2024-10-29 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib Olaparib - Ovarian Cancer, Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 185 | 2020-08-04 | 2026-06-12 |
| Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Pembrolizumab, Olaparib, Placebo for olaparib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 870 | 2020-07-06 | 2026-05-15 |
| Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer olaparib, durvalumab, durvalumab placebo - Endometrial Neoplasms | Phase 3 | Active not recruiting | AstraZeneca | 805 | 2020-05-05 | 2026-11-05 |
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) Pembrolizumab, Pemetrexed, Carboplatin - Carcinoma, Nonsquamous Non-small-cell Lung | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1003 | 2019-06-28 | 2026-09-28 |
| A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008) Pembrolizumab, Carboplatin, Paclitaxel - Carcinoma, Squamous Cell, Non-small-cell Lung | Phase 3 | Completed | Merck Sharp & Dohme LLC | 851 | 2019-06-28 | 2026-02-25 |
Showing 20 of 43. Sign in to see all of them.
Ovarian Neoplasms (19) · Breast Neoplasms (7) · Parkinson Disease 4, Autosomal Dominant Lewy Body (6) · Fallopian Tube Neoplasms (4) · Triple Negative Breast Neoplasms (3) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Endometrial Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Pancreatic Neoplasms (1)
AstraZeneca (20) · Merck Sharp & Dohme LLC (9) · National Cancer Institute (NCI) (3) · Arcagy Research (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Imunon (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · NRG Oncology (1) · National Cancer Institute, Naples (1) · Novartis Pharmaceuticals (1) · Sichuan Baili Pharmaceutical Co., Ltd. (1) · The Netherlands Cancer Institute (1) · University College, London (1)
United States (29) · Canada (27) · South Korea (27) · Spain (26) · France (25) · Japan (24) · Italy (23) · United Kingdom (23) · Germany (21) · Australia (18) · Belgium (18) · China (18) · Poland (18) · Turkey (Türkiye) (17) · Russia (16)
Fred Saad, MD (2) · Noel Clarke, M.D. (2) · Agnes Jager, MD, PhD (1) · Andrew Tutt, Doctor of Medicine (1) · Antoine Italiano (1) · Carol Aghajanian (1) · Carol Aghajanian, MD (1) · Charles Geyer, Doctor of Medicine (1) · Charlie Gourley, Prof. (1) · Chris Wilks (1) · Ding MA, PhD (1) · Eric Pujade-Lauraine, MD, PhD (1) · Gabe Sonke, MD, PhD (1)
PMID 39695768, PMID 35170751, PMID 37185961, PMID 28578601, PMID 28754483, PMID 29103871, PMID 29223478, PMID 30026002, PMID 30345884, PMID 31553234, PMID 31562758, PMID 31851799, PMID 32073954, PMID 32073956, PMID 32343890, PMID 32530766, PMID 32530768, PMID 32713836, PMID 32955174, PMID 32977221, PMID 33097567, PMID 33364840, PMID 33743851, PMID 33862001, PMID 33959007, PMID 34081848, PMID 34087573, PMID 34378365, PMID 34625424, PMID 34715071, PMID 34740331, PMID 34779646, PMID 35063276, PMID 35091440, PMID 35131903, PMID 35157830, PMID 35229141, PMID 35290101, PMID 35318277, PMID 35594464, PMID 35596182, PMID 35598359, PMID 35613997, PMID 35618629, PMID 35772665, PMID 35834777, PMID 36066851, PMID 36067615, PMID 36082969, PMID 36716415
2023 (6), 2018 (5), 2019 (5), 2017 (4), U10CA180868 (3), 2014 (1), 2016 (1), 2025 (1), U10CA180821 (1)